Loading...
•
Jun 30, 2022
Aadi Bioscience Q2 2022 Earnings Report
Aadi Bioscience reported revenue growth driven by FYARRO sales and progress in clinical trials.
Key Takeaways
Aadi Bioscience reported total revenue of $3.4 million for the second quarter of 2022, driven by FYARRO net product sales. The company continues to advance its PRECISION 1 trial and evaluate new clinical indications for nab-sirolimus.
FYARRO net product sales reached $3.4 million for the second quarter of 2022.
A product-specific permanent J-code (J9331) for FYARRO from Centers for Medicare and Medicaid Services (CMS) became effective on July 1, 2022.
The PRECISION 1 trial continues to ramp up, with activation of additional clinical trial sites and patient enrollment.
Cash and cash equivalents on June 30, 2022 were $118.7 million.
Aadi Bioscience
Aadi Bioscience
Forward Guidance
Based on current plans, the Company expects cash and cash equivalents to fund operations into 2024.